



OPTIMIZE U

A Hormone Approach to Optimizing Care



Introduction

Optimal Health

Optimal health is a dynamic balance of physical, emotional, social, spiritual, and intellectual health

Topics

Hormone optimization

Lab Work Analysis

Recovery Modalities

Objectives

1. Leave with a better understanding of what Hormone optimization is
2. Understand patients in your circle of influence who might benefit
3. Understand that some patients will need a multidisciplinary approach in their treatment plan
4. Grasp the concept that building a referral base for your practice will only grow your practice

Hormone Optimization

The goal of hormone optimization is to assess whether hormone levels in the body are below their optimal threshold and, if so, to treat this by developing a plan to improve hormone function”

NORMAL is not Optimal

Hormones

Hormones regulate > growth and development>metabolism>electrolyte balances >reproduction.

Hypothalamus >produces >releasing and inhibiting hormones that act on the pituitary gland **WHICH** stimulates the release of pituitary hormones.

pituitary hormones > act on other glands within the body

Hormone-producing glands >include the adrenal glands, ovaries and testes; the thyroid, the parathyroid, and the pancreas,

Symptoms

- > Fatigue
- > Brain fog
- > Poor Sleep
- > Low motivation
- > Poor recovery
- > Joint pain
- > Agitation
- > Moodiness
- > Weight gain
- > Loss of Lean Mass
- > Low Libido
- > Erectile Dysfunction
- > Frequent Muscle injuries

Effects of Aging

Menopause>The starting point for women. Very Accepted DX.

Ages 45>.....

MAN-opause >Goes undetected, poor assessment of labs, poor understanding of literature, guidelines based on Grade D studies.

Happens early in a mans life.

DECLINE of approx. 1% /yearly around the age of 27-28

NO ONE CAN ESCAPE it BUT we can feel better in these stages

Who's at risk for sub optimal Hormones?

- Males >30 : Dx, Occupations
- Women >30 : Dx, Meds, Occupations

“Manopause”

Peri menopause –how to dx

Post menopause-how to dx

Normal is Not Optimal

A normal result >>only means that you are within the>>> range of the average population, which includes people

>who are sick with chronic disease

- eat poorly
- are overweight
- those who are sedentary
- Those are you “in shape”

Normal

- MEN > total T 264-916 ng/dl
 - Free T 7.2-24 pg/ml

- Women > total T 4-50 ng/dl
 - Free 0-4.2 pg/ml

Rethinking low normal

The first AUA study conducted to assess population based testosterone was in 2022.

■ RESULTS:

>that men (20-44) had average test levels of 466ng/dl

>further showed traditional dx of testosterone deficiencies were performed in an age indiscriminate manner

>what we saw was young men having the same concentrations as older

Cont. Take aways

- Consider Testosterone to be a therapy offered to patients experiencing symptoms regardless of normal values.
- Lab values should not be used to definitively determine qualification of testosterone tx. ASSESS.

Hormones

- Total Testosterone
- Free Testosterone
- DHEA
- Estradiol
- Progesterone

Story Time

61 year old male

Patient CO of fatigue, low energy, joint pain, low libido (affecting marriage), depression

TX plan per provider: Adderall, Viagra for libido, Cymbalta for depression

Follow up: pt co of anxiousness, insomnia, continued joint pain, Headaches, dry mouth

POC "let's look at your testosterone"

total PSA is between 4.0 and 10.0 ng/mL.

Testosterone, Serum 414 ng/dL 264-916 02

Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Trivison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.

Date Issued: 03/15/21 1508 ET

FINAL REPORT

Page 3 of 4

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error, please call 800-282-7300

© 1995-2021 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00

”well it’s not your testosterone level so lets
make dose adjustments on the Adderall,
Viagra, and Cymbalta and follow up in 6
months”

Evaluating the full hormone panel

| | | | 17 - 19 years | 40 - 491 |
|-----------------------------------|------------|------------|---------------|----------|
| | | | >19 years | 31 - 701 |
| Free Testosterone (Direct) | 6.4 | Low | pg/mL | 7.2-24.0 |
| LH | 7.6 | | mIU/mL | 1.7-8.6 |
| FSH | 11.0 | | mIU/mL | 1.5-12.4 |
| Progesterone | 0.2 | | ng/mL | 0.0-0.5 |
| Estrone, Serum | 57 | | pg/mL | 15-65 |
| Estradiol | 21.6 | | pg/mL | 7.6-42.6 |

Testosterone = Vitality

- A study in 2020 assessed data from a twin study of Aging men.
- Looked at the relationship between circulating test levels and vitality
- Vitality was assessed with a 36 item vitality subscale
- RESULTS:
 - Found a significant interaction
 - **Men with low testosterone had significantly lower vitality**

35 year old male

Testosterone, Serum

| Test | Current Result and Flag | |
|-------------------------------------|-------------------------|-----|
| ▼ Testosterone, Serum ⁰² | 247 | Low |

Range for men 264-916

| | | | | | | |
|--|----------------|-------------|-------------|------------|--------|----------|
| ▼ Free Testosterone(Direct) ⁰¹ | 2.4 | Low | 6.9 | 10/14/2019 | pg/mL | 8.7-25.1 |
| LH ⁰² | 6.9 | | 3.5 | 03/04/2020 | mIU/mL | 1.7-8.6 |
| FSH ⁰² | 2.8 | | 2.9 | 03/04/2020 | mIU/mL | 1.5-12.4 |
| Progesterone ⁰² | <0.1 | | | | ng/mL | 0.0-0.5 |
| ▲ Estrone, Serum ⁰¹ | 67 | High | | | pg/mL | 15-65 |
| ▼ Estradiol ⁰² | <5.0 | Low | 48.7 | 02/08/2021 | pg/mL | 7.6-42.6 |

“You look like a Post Menopausal female”, but your normal”

Hormone therapy and Osteoporosis

- 2023' Endocrinal Diabetes Metabolism Case Report evaluated the reversibility of Osteoporosis with testosterone therapy. Evaluating Testosterone levels and aromatase dysfunction by PCR analysis of the CYP19A1 gene.
 - The case outlined a 44 year old athletic man who presented with low back pain
 - > dual ex ray showed severe osteoporosis while labs showed serum total testosterone of 189 ng/dl
 - > E2 was also signaling aromatase deficiency.
- !!!! Treatment included testosterone therapy for 8 years

Cont.

RESULTS>

>Bone Mass Density improved by 29% in LS and 15% in femoral hip

Take Away:

- we should consider TRT in relation to understanding aromatase factors that lead to and risk of osteoporosis as they can influence the dx of.
- findings suggest the importance of testosterone therapy but as well the aromatase of E2
- suggested a serum E2 threshold should be considered in men with a hx of Osteoporosis for tx of trt. (E2 <20pg/ml, E2 <2ng/dl)

Testosterone LAB TRAIN

| Name | 5/28/20 | 11/6/20 | 5/3/22 | 6/28/22 |
|--|---------|---------|--------|---------|
| <i>Standard Range</i> | | | | |
| Testosterone, Free <i>7.2 - 24.0 pg/mL</i> | 8.3 | 8.2 | 5.9 L | 6.0 L |
| Testosterone, Total <i>264 - 916 ng/dL</i> | 432 | 434 | 432 | 495 |

Female case

“you have the hormones of a man”, but nothing to do”

36 yr/f CO of hair growth on face, hair loss on scalp, acne,
weight gain

Tx plan per previous provider: Ran a total testosterone level
(normal)

Said you “might have PCOS”

TX: Rogaine for hair loss and pt told to lose weight, offered
birth control

Free Thyroxine Index

1.8

1.2-4.9

Testosterone, Serum

41

ng/dL

8-48

02

FSH+LH+Prog+E2+TestF+DHEA+E1
Dehydroepiandrosterone (DHEA) ^A

| | | | | | |
|-----------------------------------|------|------|------------------|--------------|----|
| | 1436 | High | ng/dL | 31-701 | 01 |
| | | | Age | | |
| | | | 1 - 5 years | 0 - 67 | |
| | | | 6 - 7 years | 0 - 110 | |
| | | | 8 - 10 years | 0 - 185 | |
| | | | 11 - 12 years | 0 - 201 | |
| | | | 13 - 14 years | 0 - 318 | |
| | | | 15 - 16 years | 39 - 481 | |
| | | | 17 - 19 years | 40 - 491 | |
| | | | >19 years | 31 - 701 | |
| Free Testosterone (Direct) | 6.3 | High | pg/mL | 0.0-4.2 | 01 |
| LH | 8.2 | | mIU/mL | | 02 |
| | | | Adult Female: | | |
| | | | Follicular phase | 2.4 - 12.6 | |
| | | | Ovulation phase | 14.0 - 95.6 | |
| | | | Luteal phase | 1.0 - 11.4 | |
| | | | Postmenopausal | 7.7 - 58.5 | |
| FSH | 5.1 | | mIU/mL | | 02 |
| | | | Adult Female: | | |
| | | | Follicular phase | 3.5 - 12.5 | |
| | | | Ovulation phase | 4.7 - 21.5 | |
| | | | Luteal phase | 1.7 - 7.7 | |
| | | | Postmenopausal | 25.8 - 134.8 | |
| Progesterone | 0.4 | | ng/mL | | 02 |
| | | | Follicular phase | 0.1 - 0.9 | |
| | | | Luteal phase | 1.8 - 23.9 | |
| | | | Ovulation phase | 0.1 - 12.0 | |
| | | | Pregnant | | |
| | | | First trimester | 11.0 - 44.3 | |
| | | | Second trimester | 25.4 - 83.3 | |
| | | | Third trimester | 58.7 - 214.0 | |
| | | | Postmenopausal | 0.0 - 0.1 | |
| Estrone, Serum | 102 | | pg/mL | | 01 |

PCOS

- Higher than normal Testosterone levels (cyclic)
- Acne
- Hair growth/Loss
- Painful menstrual periods
- Weight gain/difficulty losing weight
- Difficulty getting pregnant
- Multiple Miscarriages

Hx of multiple fractures, joint pain, osteoporosis

| | | | | | | |
|-----------|------|------------------|-------|---|---------|----|
| | | Luteal phase | 54 | - | 179 | |
| | | Pregnancy: | | | | |
| | | 1st trimester | 247 | - | 2774 | |
| | | 2nd trimester | 569 | - | 5781 | |
| | | Postmenopausal: | | | | |
| | | with ERT | 51 | - | 488 | |
| | | without ERT | 31 | - | 100 | |
| Estradiol | <5.0 | | | | | 02 |
| | | | pg/mL | | | |
| | | Adult Female: | | | | |
| | | Follicular phase | 12.5 | - | 166.0 | |
| | | Ovulation phase | 85.8 | - | 498.0 | |
| | | Luteal phase | 43.8 | - | 211.0 | |
| | | Postmenopausal | <6.0 | - | 54.7 | |
| | | Pregnancy | | | | |
| | | 1st trimester | 215.0 | - | >4300.0 | |

Roche ECLIA methodology

Menopause

| | | | |
|----------------------------|------|------------------|--------------|
| | | 17 - 19 years | 40 - 491 |
| | | >19 years | 31 - 701 |
| Free Testosterone (Direct) | 2.2 | pg/mL | 0.0-4.2 |
| LH | 23.4 | mIU/mL | |
| | | Adult Female: | |
| | | Follicular phase | 2.4 - 12.6 |
| | | Ovulation phase | 14.0 - 95.6 |
| | | Luteal phase | 1.0 - 11.4 |
| | | Postmenopausal | 7.7 - 58.5 |
| FSH | 48.1 | mIU/mL | |
| | | Adult Female: | |
| | | Follicular phase | 3.5 - 12.5 |
| | | Ovulation phase | 4.7 - 21.5 |
| | | Luteal phase | 1.7 - 7.7 |
| | | Postmenopausal | 25.8 - 134.8 |
| Progesterone | 0.4 | ng/mL | |
| | | Follicular phase | 0.1 - 0.9 |
| | | Luteal phase | 1.8 - 23.9 |
| | | Ovulation phase | 0.1 - 12.0 |
| | | Pregnant | |
| | | First trimester | 11.0 - 44.3 |
| | | Second trimester | 25.4 - 83.3 |
| | | Third trimester | 58.7 - 214.0 |
| | | Postmenopausal | 0.0 - 0.1 |

“you’re Low Normal, but still Normal”

Patient 45 yr/M CO of sleep, fatigue, low motivation, and low libido:

Tx was Ambien and Viagra and told to decrease stress

Pt: but isn't poor sleep a symptom of low testosterone?

Provider: it is but your levels are normal so it can't be that

POC: follow up in 6 months

You're Normal-"clean up your diet"

Testosterone, Serum 360 ng/dL 264-916 02

Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old.

Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.

Cont.

| TESTS | RESULT | FLAG | UNITS | REFERENCE INTERVAL | LAB |
|--|--------|------|---------------|--------------------|-----|
| FSH+LH+Prog+E2+TestF+DHEA+E1 | | | | | |
| Dehydroepiandrosterone (DHEA) ^A | 377 | | ng/dL | 31-701 | 01 |
| | | | Age | | |
| | | | 1 - 5 years | 0 - 67 | |
| | | | 6 - 7 years | 0 - 110 | |
| | | | 8 - 10 years | 0 - 185 | |
| | | | 11 - 12 years | 0 - 201 | |
| | | | 13 - 14 years | 0 - 318 | |
| | | | 15 - 16 years | 39 - 481 | |
| | | | 17 - 19 years | 40 - 491 | |
| | | | >19 years | 31 - 701 | |
| Free Testosterone (Direct) | 9.0 | | pg/mL | 7.2-24.0 | 01 |
| LH | 6.6 | | mIU/mL | 1.7-8.6 | 02 |
| FSH | 5.7 | | mIU/mL | 1.5-12.4 | 02 |
| Progesterone | 0.3 | | ng/mL | 0.0-0.5 | 02 |
| Estrone, Serum | 54 | | pg/mL | 15-65 | 01 |
| Estradiol | 14.3 | | pg/mL | 7.6-42.6 | 02 |
| Roche ECLIA methodology | | | | | |

Why is HRT scary

ARGUMENT was

“NO Randomized clinical trials have been conducted in men to assess cardiovascular endpoints”

(JAMA) Transverse Trial 2023'

Cardiovascular Safety in TRT

> This trial was done to resolve the controversy with TRT and Cardiovascular disease that began in 2015 when the FDA made the decision to place a black box warning of (strokes, Heart Attacks, and blood clots).

> This was based on poor quality studies, invalid observational insurance claims research performed method of a retrospective chart review from hospital data bases (Grade D literature) Vigen (2013) and Finkle (2013)

What the Transverse Trial showed

- >Grade A study
- >Double blinded RCT
- >ALL participants had a hx of CVD or were at risk and had low testosterone

Testosterone Therapy failed to increase cardiovascular events above the placebo group

Cont

Guidelines were developed on skewed data and research. Ironically pharmaceutical companies funded the research.

WHI trial

(Women's Health Initiative study)

Where to go

Understanding healthcare and insurance
approved labs

Recovery Optimization

- Cold therapy
- Heat Therapy
- Compression

Peptide Optimization

- Sarcotropin
- Sermorelin
- Semaglutide
- Tirzepatide

Who Needs to be Optimized

Patients are talking Are we Listening

- When to refer
- What are patients saying that should lead to a referral
- What are common statements that should lead you to offer a referral
- Things to ask to ensure it was a proper referral

Building Your Practice

Referrals to another provider do not LEAD to losing a patient. It leads to MORE LEADS